NO924940L - Polycykliske guaninderivater - Google Patents

Polycykliske guaninderivater

Info

Publication number
NO924940L
NO924940L NO92924940A NO924940A NO924940L NO 924940 L NO924940 L NO 924940L NO 92924940 A NO92924940 A NO 92924940A NO 924940 A NO924940 A NO 924940A NO 924940 L NO924940 L NO 924940L
Authority
NO
Norway
Prior art keywords
aryl
alkyl
heteroaryl
hydrogen
pct
Prior art date
Application number
NO92924940A
Other languages
English (en)
Other versions
NO924940D0 (no
Inventor
Bernard R Neustadt
Neil A Lindo
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO924940L publication Critical patent/NO924940L/no
Publication of NO924940D0 publication Critical patent/NO924940D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Filtering Materials (AREA)

Abstract

Nye, polysykliske guanin- derivater av formel (I) og (I'), hvori ; J er oksygen eller svovel, R1 er hydro- . gen, alkyl eller alkyl substituert med aryl eller hydroksy; R3 er hydrogen, aryl, heteroaryl, cykloalkyl, alkyl eller alkyl substituert med aryl, hetero- aryl, hydroksy, alkoksy, amino, mono- alkylamino eller dialkylamino, eller -(CH2)mTCOR30 hvori m er et helt tall fra l til 6, T er oksygen eller -NH- og R20 er hydrogen, aryl, heteroaryl, alkyl eller alkyl substituert med aryl eller heteroaryl; R3 er hydrogen, halogen, trifluormetyl, alkoksy, alkyltio, alkyl, cykloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroksy- alkylamino, aminoalkylamino, karboksy, alkoksykarbonyl eller aminokarbonyl eller alkyl substituert med aryl, hydroksy, alkoksy, amino, monoalkylamino eller dialkylamino; R», Rto, R= og R* be- tegner uavhengig hydrogen, alkyl, cyklo- alkyl eller aryl; eller (R- og Rb) eller (R= og R*) eller (Rb og R=) kan fullføre en mettet ring på 5 til 7 karbonatomer, eller (R«* og Rto) tatt sammen og (Rto og R=) tatt sammen, hver fullfører en mettet ring på 5 til 7 karbonatomer, hvori hver ring eventuelt kan inneholde et svovel- eller oksygenatom og hvis karbonatomer eventuelt kan være substi- tuert med en eller flere av følgende: alkenyl, alkynyl, hydroksy, karboksy, alkoksykarbonyl, alkyl eller alkyl sub- stituert med hydroksy, karboksy eller alkoksykarbonyl; eller slik mettet ring kan ha to tilstøtende karbonatomer som deles med en tilstøtende arylring; og n er O eller l. Forbindelsene av formel (I) og (I') er anvendbare som antihyper- tensive midler, muskelrelakserende midler og bronkodilaterende midler.
NO924940A 1990-06-21 1992-12-18 Polycykliske guaninderivater NO924940D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
NO924940L true NO924940L (no) 1992-12-18
NO924940D0 NO924940D0 (no) 1992-12-18

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924940A NO924940D0 (no) 1990-06-21 1992-12-18 Polycykliske guaninderivater

Country Status (21)

Country Link
US (1) US5393755A (no)
EP (1) EP0538332B1 (no)
JP (1) JPH0747589B2 (no)
KR (1) KR960004532B1 (no)
AT (1) ATE155786T1 (no)
AU (1) AU651607B2 (no)
CA (1) CA2085733C (no)
CZ (1) CZ281920B6 (no)
DE (1) DE69126980T2 (no)
FI (1) FI925731A (no)
HU (1) HUT65623A (no)
IE (1) IE912126A1 (no)
IL (1) IL98559A0 (no)
NO (1) NO924940D0 (no)
NZ (1) NZ238609A (no)
OA (1) OA09723A (no)
PL (1) PL169481B1 (no)
RU (1) RU2080322C1 (no)
TW (1) TW197441B (no)
WO (1) WO1991019717A1 (no)
ZA (1) ZA914727B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270118B (no) * 1993-02-26 1996-02-11 Schering Corp
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2302835T3 (es) * 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
JP2005509038A (ja) 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
ATE363483T1 (de) * 2003-07-31 2007-06-15 Schering Corp Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
JP4377881B2 (ja) * 2003-08-01 2009-12-02 日本曹達株式会社 フェニルアゾール化合物、製造法および抗酸化薬
BRPI0416202A (pt) * 2003-11-21 2006-12-26 Schering Corp formulações inibidoras de fosfodiesterase v
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
ES2645371T3 (es) * 2005-06-06 2017-12-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
KR101388688B1 (ko) * 2005-11-09 2014-04-24 토소가부시키가이샤 퍼플루오로알킬기를 가진 핵산 염기 및 그 제조방법
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
JP5837278B2 (ja) * 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
BRPI0812909A2 (pt) * 2007-06-21 2014-12-09 Schering Corp Derivados de guanina policíclica e métodos de uso dos mesmos.
CN101969774A (zh) 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
EP2358204B1 (en) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
CN102223799A (zh) 2008-12-06 2011-10-19 细胞内治疗公司 有机化合物
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
US8536159B2 (en) * 2008-12-06 2013-09-17 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
MX2017003646A (es) 2014-09-17 2017-07-13 Intra Cellular Therapies Inc Compuestos y metodos.
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. INNOVATIVE USES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
ZA902282B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives

Also Published As

Publication number Publication date
US5393755A (en) 1995-02-28
DE69126980D1 (de) 1997-09-04
WO1991019717A1 (en) 1991-12-26
ZA914727B (en) 1992-03-25
PL169481B1 (pl) 1996-07-31
JPH05508647A (ja) 1993-12-02
HU9204032D0 (en) 1993-03-29
EP0538332A1 (en) 1993-04-28
PL297299A1 (no) 1992-07-13
CA2085733C (en) 1996-03-05
EP0538332B1 (en) 1997-07-23
OA09723A (en) 1993-08-30
NO924940D0 (no) 1992-12-18
DE69126980T2 (de) 1998-01-08
ATE155786T1 (de) 1997-08-15
RU2080322C1 (ru) 1997-05-27
CZ374992A3 (en) 1993-10-13
IE912126A1 (en) 1992-01-01
AU8199291A (en) 1992-01-07
IL98559A0 (en) 1992-07-15
JPH0747589B2 (ja) 1995-05-24
FI925731A0 (fi) 1992-12-17
AU651607B2 (en) 1994-07-28
TW197441B (no) 1993-01-01
NZ238609A (en) 1993-12-23
FI925731A (fi) 1992-12-17
KR960004532B1 (ko) 1996-04-06
CA2085733A1 (en) 1991-12-22
CZ281920B6 (cs) 1997-04-16
HUT65623A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
ATE155786T1 (de) Polycyclische guaninderivate
ATE275134T1 (de) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
ATE155133T1 (de) Piperazinderivate als 5-ht antagonisten
DE69327913D1 (de) 1,2,4-Oxadiazolyl-Phenoxyalkyl-isoxazole und ihre Anwendung als antivirale Mittel
DK0678090T3 (da) Piperazinderivater
BR0109146A (pt) Compostos disazo reativos com fibras
ATE225335T1 (de) Amide derivate als 5-ht1a liganden
DE69416311D1 (de) Verwendung von cephem-derivaten als antimetastatische mittel
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
ATE172724T1 (de) Anthelmintische benzimidazole
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
ATE110367T1 (de) Kalziumantagonisten.
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
ATE119883T1 (de) Thioformamidderivate.